Adalimumab
- PDF / 169,626 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 166 Views
1
S
Duodenal ulcers: case report A 66-year-old woman developed duodenal ulcers during treatment with adalimumab for psoriasis. The woman, who had a 30-year history of psoriasis presented with severe plaque psoriasis associated with nail involvement and psoriatic arthritis in 2014. At that time she was started on monotherapy with adalimumab [route and dosage not stated]. She was on adalimumab for the past 3 years (2014–2017). She was hospitalised in emergency department in the summer of 2017 for upper digestive bleeding (melena), nausea, abdominal pain and severe anemia with no previous gastrointestinal complaints. She underwent upper gastro-intestinal endoscopy, which showed two ulcers of 25mm and 30mm, respectively localized at bulbar level and D2 area, classified as Forrest III. Hence, the woman’s adalimumab therapy was stopped and she was treated with unspecified proton-pump inhibitors with a favorable outcome. Author comment: "On the drug label there is a long list of adverse reactions. . .uncommon (0.1% to 1%): cholecystitis, cholelithiasis, gastroenteritis, gastrointestinal hemorrhage, gastritis, dyspepsia, gastrointestinal disorder, gastrointestinal hemorrhage". Chiriac A, et al. Forrest III duodenal ulcers during treatment with adalimumab for psoriasis. Journal of Dermatological Treatment 30: 784, No. 8, Dec 2019. Available from: URL: http://doi.org/10.1080/09546634.2019.1572859 803435940 Romania
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
Data Loading...
